91 related articles for article (PubMed ID: 23588667)
1. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair.
Xu J; Zhu W; Xu W; Cui X; Chen L; Ji S; Qin Y; Yao W; Liu L; Liu C; Long J; Li M; Yu X
Int J Oncol; 2013 Jun; 42(6):2046-52. PubMed ID: 23588667
[TBL] [Abstract][Full Text] [Related]
2. MDC1 interacts with Rad51 and facilitates homologous recombination.
Zhang J; Ma Z; Treszezamsky A; Powell SN
Nat Struct Mol Biol; 2005 Oct; 12(10):902-9. PubMed ID: 16186822
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Xu J; Zhu W; Xu W; Yao W; Zhang B; Xu Y; Ji S; Liu C; Long J; Ni Q; Yu X
Curr Mol Med; 2013 Mar; 13(3):387-400. PubMed ID: 23331011
[TBL] [Abstract][Full Text] [Related]
4. Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin.
Watanabe S; Ichimura T; Fujita N; Tsuruzoe S; Ohki I; Shirakawa M; Kawasuji M; Nakao M
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12859-64. PubMed ID: 14555760
[TBL] [Abstract][Full Text] [Related]
5. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
[TBL] [Abstract][Full Text] [Related]
6. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes.
Yaqinuddin A; Abbas F; Naqvi SZ; Bashir MU; Qazi R; Qureshi SA
Biosci Rep; 2008 Dec; 28(6):319-26. PubMed ID: 18666890
[TBL] [Abstract][Full Text] [Related]
7. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
Liu YC; Chang PY; Chao CC
Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
[TBL] [Abstract][Full Text] [Related]
8. [Activation of multiple tumor suppressor genes by MBD1 siRNA in pancreatic cancer cell line BxPC-3].
Xu J; Liu C; Yu XJ; Jin C; Fu DL; Ni QX
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1948-51. PubMed ID: 19062732
[TBL] [Abstract][Full Text] [Related]
9. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals.
Lou Z; Minter-Dykhouse K; Franco S; Gostissa M; Rivera MA; Celeste A; Manis JP; van Deursen J; Nussenzweig A; Paull TT; Alt FW; Chen J
Mol Cell; 2006 Jan; 21(2):187-200. PubMed ID: 16427009
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of expression of the chromatin remodeling gene, SNF2L, selectively leads to DNA damage, growth inhibition, and cancer cell death.
Ye Y; Xiao Y; Wang W; Wang Q; Yearsley K; Wani AA; Yan Q; Gao JX; Shetuni BS; Barsky SH
Mol Cancer Res; 2009 Dec; 7(12):1984-99. PubMed ID: 19996304
[TBL] [Abstract][Full Text] [Related]
11. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
12. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
13. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F; Friese O; Pantel K; Schwarzenbach H
Mol Cancer Res; 2007 Jul; 5(7):749-59. PubMed ID: 17634428
[TBL] [Abstract][Full Text] [Related]
14. LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.
Wang S; Zou Z; Luo X; Mi Y; Chang H; Xing D
Oncogene; 2018 Jun; 37(24):3243-3259. PubMed ID: 29545602
[TBL] [Abstract][Full Text] [Related]
15. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.
Tran HM; Shi G; Li G; Carney JP; O'Malley B; Li D
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):477-84. PubMed ID: 15467621
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hsp90 compromises the DNA damage response to radiation.
Dote H; Burgan WE; Camphausen K; Tofilon PJ
Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.
Zeng Q; Wang Z; Liu C; Gong Z; Yang L; Jiang L; Ma Z; Qian Y; Yang Y; Kang H; Hong S; Bu Y; Hu G
Mol Cell Biochem; 2016 Jul; 418(1-2):137-46. PubMed ID: 27334757
[TBL] [Abstract][Full Text] [Related]
18. MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways.
Lou Z; Minter-Dykhouse K; Wu X; Chen J
Nature; 2003 Feb; 421(6926):957-61. PubMed ID: 12607004
[TBL] [Abstract][Full Text] [Related]
19. MAD2 interacts with DNA repair proteins and negatively regulates DNA damage repair.
Fung MK; Han HY; Leung SC; Cheung HW; Cheung AL; Wong YC; Ling MT; Wang X
J Mol Biol; 2008 Aug; 381(1):24-34. PubMed ID: 18597777
[TBL] [Abstract][Full Text] [Related]
20. NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors.
Xu X; Stern DF
FASEB J; 2003 Oct; 17(13):1842-8. PubMed ID: 14519663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
